Table 3 Factors associated with ART uptake and VL suppression among HIV-infected patients in care in the ARCs (2011), Belgium
ART uptake | VL suppression | ||||||
|---|---|---|---|---|---|---|---|
Characteristic | On ART | OR for no ART uptake (95 % CI) | AORa for no ART uptake (95 % CI) | AORb for no ART uptake (95 % CI) | Undetectable VL | OR for detectable VL (95 % CI) | AORa for detectable VL (95 % CI) |
Sex | |||||||
Male | 84.5 % | 1 | 1 | 1 | 83.7 % | 1 | 1 |
Female | 84.9 % | 0.97 (0.87–1.09) | 1.38 (1.14–1.67) | 1.16 (0.85–1.58) | 82.9 % | 1.06 (0.93–1.19) | 0.84 (0.70–1.01) |
Age at diagnosis | |||||||
<40 years | 84.0 % | 1 | 1 | 1 | 82.3 % | 1 | 1 |
≥40 years | 85.5 % | 0.89 (0.78–1.01) | 0.88 (0.76–1.02) | 0.74 (0.60–0.91) | 85.2 % | 0.81 (0.70–0.93) | 0.83 (0.71–0.97) |
Way of transmission | |||||||
Heterosexual | 85.9 % | 1 | 1 | 1 | 82.6 % | 1 | 1 |
MSM | 81.8 % | 1.36 (1.19–1.55) | 1.54 (1.27–1.88) | 0.98 (0.73–1.32) | 84.8 % | 0.85 (0.74–0.98) | 0.88 (0.72–1.07) |
IDU | 85.6 % | 1.02 (0.66–1.59) | 1.01 (0.64–1.60) | 0.75 (0.27–2.11) | 82.5 % | 1.01 (0.65–1.56) | 1.04 (0.66–1.65) |
Nationality | |||||||
Belgian | 83.8 % | 1 | 1 | 1 | 85.1 % | 1 | 1 |
SSA | 86.4 % | 0.81 (0.71–0.93) | 0.87 (0.73–1.05) | 0.89 (0.65–1.21) | 81.3 % | 1.31 (1.14–1.52) | 1.25 (1.04–1.51) |
European | 82.5 % | 1.10 (0.88–1.37) | 1.14 (0.91–1.44) | 0.84 (0.61–1.15) | 84.2 % | 1.07 (0.83–1.38) | 1.01 (0.77–1.32) |
Other | 81.9 % | 1.14 (0.90–1.45) | 1.13 (0.89–1.45) | 1.17 (0.81–1.67) | 81.1 % | 1.33 (1.03–1.73) | 1.21 (0.92–1.59) |
Reason for testing | |||||||
Patient’s request | 76.7 % | 1 | 1 | 1 | 82.6 % | 1 | 1 |
Clinical arguments | 86.2 % | 0.53 (0.45–0.62) | 0.57 (0.48–0.67) | 0.77 (0.61–0.97) | 82.9 % | 0.98 (0.82–1.18) | 0.96 (0.79–1.16) |
Preoperative | 78.8 % | 0.89 (0.62–1.27) | 0.95 (0.64–1.40) | 1.82 (0.95–3.52) | 88.2 % | 0.64 (0.38–1.07) | 0.65 (0.38–1.11) |
Other | 83.5 % | 0.65 (0.54–0.78) | 0.73 (0.60–0.89) | 0.92 (0.68–1.25) | 83.7 % | 0.93 (0.75–1.15) | 0.87 (0.69–1.10) |
CD4 at first visit | |||||||
CD4≥350 | 58.5 % | 1 | 1 | / | 76.5 % | 1 | 1 |
CD4≥200 & <350 | 88.0 % | 0.19 (0.15–0.25) | 0.19 (0.14–0.26) | / | 78.2 % | 0.91 (0.70–1.17) | 0.83 (0.62–1.10) |
CD4<200 | 94.0 % | 0.09 (0.06–0.13) | 0.09 (0.06–0.14) | / | 74.6 % | 1.10 (0.87–1.41) | 1.03 (0.78–1.37) |
Time since HIV diagnosis | |||||||
<1 year | 54.2 % | 1 | 1 | 1 | 49.2 % | 1 | 1 |
1 – <5 years | 78.3 % | 0.33 (0.28–0.39) | 0.32 (0.27–0.39) | 0.26 (0.21–0.33) | 81.5 % | 0.22 (0.18–0.27) | 0.22 (0.17–0.27) |
5 – <10 years | 89.3 % | 0.14 (0.12–0.17) | 0.13 (0.11–0.16) | 0.12 (0.07–0.19) | 88.4 % | 0.13 (0.10–0.16) | 0.12 (0.09–0.15) |
≥10 years | 94.5 % | 0.07 (0.06–0.08) | 0.06 (0.05–0.07) | / | 85.9 % | 0.16 (0.13–0.20) | 0.14 (0.11–0.18) |